NYSE Content Advisory: Pre-Market update + ICE Data Projects Coldest Stretch for U.S. in Decades
NEW YORK, Jan. 26, 2026 /PRNewswire/ -- The New York Stock Exchange…
Cisco Launches New Cisco 360 Partner Program, Built with Partners for the AI Era
The new program helps customers reach transformative AI outcomes fasterNews summary: Now live,…
Beko Secures #1 Spot for Household Durables Industry in the Corporate Knights Global 100
Top ranking comes alongside recent acknowledgements from S&P Global, CDP and EcoVadis,…
Banqup secures additional shareholder funding, recalibrates covenants with Francisco Partners and signs an agreement for the sale of Baltic operations
Press Release - Inside Information La Hulpe, Belgium –26 January 2026, 7:00…
FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment…
Accevo Receives Frost & Sullivan’s 2025 European Enabling Technology Leadership Recognition for Manufacturing Software in Smart Factories
The company is acknowledged for enabling digital transformation, performance-driven smart manufacturing, and…
MEDIROM Forms New Special Mission Team to Drive World ID Adoption Across 3,000 Locations Through Partnership with Tools for Humanity
TOKYO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters:…
Kondo Launches Sales Tools for Teams Focused on Faster LinkedIn Messaging Without Automation
SAN FRANCISCO, Jan. 24, 2026 (GLOBE NEWSWIRE) -- Kondo, a leading sales…
CATL and the Ellen Macarthur Foundation Set Direction for Circular EV Batteries with Landmark Whitepaper
DAVOS, Switzerland, Jan. 24, 2026 /PRNewswire/ -- Leading The Charge – Turning risk…
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
January 23, 2026 17:25 ET | Source: Immunovant Inc. DURHAM, N.C. and…
